CSPC PHARMACEUTICAL (CVG BE) stock market data APIs
€1.1394
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
CSPC PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for CVG.BE.
Prev. Close
1.1394
Open
1.1394
High
1.1394
Low
1.1394
52 wk Range
0.4946-1.227
Market Cap
11 678 M
Dividends (Yield)
0.0963
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSPC PHARMACEUTICAL data using free add-ons & libraries
Get CSPC PHARMACEUTICAL Fundamental Data
CSPC PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-22
- EPS/Forecast: 0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSPC PHARMACEUTICAL News
New
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Co...
Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168 (AlaMab Therapeutics in collaboration with ...
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Madrigal Pharmaceuticals, Inc. License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resm...
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
Rakovina Therapeutics Inc VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
